Holen Sie sich die Stockscreener-App
0.868
4.48%
0.0372
Vorhandelsmarkt:
.84
-0.028
-3.23%
Schlusskurs vom Vortag:
$0.8308
Offen:
$0.815
24-Stunden-Volumen:
286.66K
Relative Volume:
0.17
Marktkapitalisierung:
$5.09M
Einnahmen:
$4.70M
Nettoeinkommen (Verlust:
$-4.99M
KGV:
-0.1352
EPS:
-6.42
Netto-Cashflow:
$-5.29M
1W Leistung:
+0.99%
1M Leistung:
-56.60%
6M Leistung:
-92.14%
1J Leistung:
-96.43%
1-Tages-Spanne:
$0.795
$0.89
1-Wochen-Bereich:
$0.795
$0.915
52-Wochen-Spanne:
$0.7106
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Firmenname
Salarius Pharmaceuticals Inc
Sektor
Branche
Telefon
346-772-0346
Adresse
2450 HOLCOMBE BLVD, HOUSTON
Vergleichen Sie SLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.868 | 4.87M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Aktie (SLRX) Neueste Nachrichten
Salarius Pharmaceuticals Inc. (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Taking the lead: Salarius Pharmaceuticals Inc (SLRX) - Setenews
Salarius Pharmaceuticals (NASDAQ:SLRX) Upgraded at Wall Street Zen - Defense World
Why Salarius Pharmaceuticals Inc. stock is a must watch in 20252025 Trade Ideas & Real-Time Chart Breakout Alerts - Newser
Can Salarius Pharmaceuticals Inc. (FP10) stock resist broad market declinesTrend Reversal & Accurate Entry/Exit Alerts - Newser
Is Salarius Pharmaceuticals Inc. stock attractive for income investorsProduct Launch & Daily Entry Point Alerts - Newser
Can Salarius Pharmaceuticals Inc. (FP10) stock sustain breakout momentumJuly 2025 Reactions & AI Powered Market Entry Ideas - Newser
Salarius Pharmaceuticals (SLRX) Stock Analysis Report | Financials & Insights - Benzinga
How Salarius Pharmaceuticals Inc. (FP10) stock responds to job market shiftsWeekly Volume Report & Smart Money Movement Alerts - Newser
Salarius Pharmaceuticals, Inc. (SLRX) 7.9% in After-hours: Collaboration with Texas Biomedical Research Institute Sparks Interest - Stocks Telegraph
Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing - marketscreener.com
Salarius Pharmaceuticals to collaborate with Texas Biomedical Research Institute on avian flu study - marketscreener.com
SLRX Collaborates with Texas Research Institute for Influenza Te - GuruFocus
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewswire
Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spending2025 Trade Ideas & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikes2025 Price Action Summary & Consistent Profit Trading Strategies - moha.gov.vn
Hanish of Salarius Pharma buys $3740 in shares - Investing.com India
Hanish of Salarius Pharma buys $3740 in shares By Investing.com - Investing.com South Africa
[Form 4] Salarius Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
What analysts say about Salarius Pharmaceuticals Inc stockDividend Yield Trends & Technical + Fundamental = Smarter Investing - earlytimes.in
Salarius Pharmaceuticals Inc (SLRX) can make a big difference with a little luck - Setenews
[Form 3] Salarius Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
SLRX Stock Institutional Owners - Quiver Quantitative
How Salarius Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
Salarius Pharmaceuticals Exec VP Finance, CFO Mark J Rosenblum Acquires 20,000 Shares - TradingView
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol SLRX - MarketScreener
Why Salarius Pharmaceuticals Inc. (FP10) stock stays resilientJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Down 8.3% – Here’s Why - Defense World
Will Salarius Pharmaceuticals Inc. (FP10) stock benefit from infrastructure bill - newser.com
Ranking Salarius Pharmaceuticals Inc. among high performing stocks via toolsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
When is the best time to exit Salarius Pharmaceuticals Inc.Market Trend Summary & Free Weekly Watchlist of Top Performers - newser.com
What catalysts could drive Salarius Pharmaceuticals Inc. stock higher - newser.com
Applying Elliott Wave Theory to Salarius Pharmaceuticals Inc.Portfolio Profit Report & Low Risk Profit Maximizing Plans - newser.com
Salarius clarifies Nasdaq listing status, refutes S&P CapIQ error By Investing.com - Investing.com Australia
[8-K] Salarius Pharmaceuticals, Inc. Reports Material Event | SLRX SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Says S&P Capital IQ Platform Misreported Nasdaq Status After Merger - marketscreener.com
Finanzdaten der Salarius Pharmaceuticals Inc-Aktie (SLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):